🇺🇸 FDA
Pipeline program

E6005

E6005-J081-101

Phase 2 small_molecule completed

Quick answer

E6005 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Organon Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Organon Pharma Pty Ltd
Indication
Atopic Dermatitis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials